| All patients ( N  = 303) | Event ( N  = 87) | Crude HR (95% CI) | P | Adjusted HRa(95% CI) | P | ||
---|---|---|---|---|---|---|---|---|
 | N | % | N | % | ||||
F/U duration (median), days | 67-1930 (1540) | 67-1930 (1161) | Â | Â | Â | Â | ||
Age, mean (SD) | 46.6 (10.7) | 46.5 (11.4) | 0.99 (0.79-1.23) | 0.897 | 1.00 (0.98-1.02) | 0.911 | ||
  < 39 | 81 | 26.7 | 25 | 28.7 | 1.00 |  | 1.00 |  |
  40-49 | 108 | 35.6 | 29 | 33.3 | 0.85 (0.50-1.46) | 0.557 | 1.21 (0.68-2.16) | 0.525 |
  50 ≤ | 114 | 37.7 | 33 | 37.9 | 0.83 (0.49-1.41) | 0.496 | 0.97 (0.54-1.76) | 0.926 |
Menopausal statusb | Â | Â | Â | Â | Â | Â | Â | Â |
  Premenopausal | 191 | 63.3 | 54 | 62.1 | 1.00 |  | 1.00 |  |
  Postmenopausal | 111 | 36.8 | 33 | 37.9 | 1.02 (0.66-1.58) | 0.915 | 1.01 (0.62-1.64) | 0.982 |
BMI, mean (SD) | 23.3 (3.17) | 23.5 (3.39) | Â | Â | Â | Â | ||
  < 25 kg/m2 | 229 | 75.6 | 62 | 71.3 | 1.00 |  | 1.00 |  |
  ≥ 25 kg/m2 | 74 | 24.4 | 25 | 28.7 | 1.11 (0.70-1.77) | 0.665 | 1.10 (0.66-1.81) | 0.723 |
TNM stage | Â | Â | Â | Â | Â | Â | Â | Â |
  I | 115 | 38 | 18 | 20.7 | 1.00 |  | 1.00 |  |
  IIA -IIB | 123 | 40.5 | 36 | 41.4 | 1.89 (1.06-3.37) | 0.031 | 1.46 (0.78-2.73) | 0.242 |
  IIIA -IIIC | 65 | 21.5 | 33 | 37.9 | 3.97 (2.20-7.13) | <.0001 | 4.41 (2.27-8.57) | <.0001 |
Tumor size | Â | Â | Â | Â | Â | Â | Â | Â |
  < 2 cm | 159 | 52.5 | 26 | 29.9 | 1.00 |  | 1.00 |  |
  ≥ 2 cm | 144 | 47.5 | 61 | 70.1 | 2.78 (1.74-4.44) | <.0001 | 2.42 (1.46-4.02) c | <.0001 |
Lymph node status | Â | Â | Â | Â | Â | Â | Â | Â |
  Negative | 170 | 56.1 | 40 | 46 | 1.00 |  | 1.00 |  |
  Positive | 133 | 43.9 | 47 | 54 | 1.54 (1.27-1.86) | <.0001 | 1.47 (0.93-2.31) d | 0.092 |
Histologic gradeb | Â | Â | Â | Â | Â | Â | Â | Â |
  I-II | 160 | 55.4 | 32 | 39 | 1.00 |  | 1.00 |  |
  III | 129 | 44.6 | 50 | 61 | 2.11 (1.35-3.30) | 0.001 | 1.36 (0.81-2.28) | 0.248 |
Nuclear gradeb | Â | Â | Â | Â | Â | Â | Â | Â |
  I-II | 145 | 54.6 | 33 | 39.8 | 1.00 |  | 1.00 |  |
  III | 133 | 45.4 | 50 | 60.2 | 1.96 (1.26-3.06) | 0.003 | 1.16 (0.70-1.95) | 0.564 |
ER status | Â | Â | Â | Â | Â | Â | Â | Â |
  Positive | 173 | 57.1 | 36 | 41.4 | 1.00 |  | 1.00 |  |
  Negative | 130 | 42.9 | 51 | 58.6 | 2.40 (1.56-3.70) | <.0001 | 2.34 (1.46-3.75) | <.0001 |
PR status | Â | Â | Â | Â | Â | Â | Â | Â |
  Positive | 159 | 52.5 | 33 | 37.9 | 1.00 |  | 1.00 |  |
  Negative | 144 | 47.5 | 54 | 62.1 | 2.19 (1.41-3,.39) | 0.001 | 1.45 (0.79-2.65) | 0.235 |
Adjuvant chemotherapyb | Â | Â | Â | Â | Â | Â | Â | |
  Yes | 216 | 72.7 | 74 | 87.1 | 1.00 |  | 1.00 |  |
  No | 81 | 27.3 | 11 | 12.9 | 0.34 (0.17-0.65) | 0.001 | 0.61 (0.26-1.41) | 0.249 |
Radiation therapyb | Â | Â | Â | Â | Â | Â | Â | Â |
  Yes | 184 | 61.7 | 49 | 57.7 | 1.00 |  | 1.00 |  |
  No | 114 | 38.3 | 36 | 42.4 | 1.26 (0.81-1.94) | 0.310 | 2.08 (1.24-3.49) | 0.006 |
Hormone receptor therapyb | Â | Â | Â | Â | Â | Â | Â | |
  Yes | 198 | 66.2 | 41 | 47.7 | 1.00 |  | 1.00 |  |
  No | 101 | 33.8 | 45 | 52.3 | 2.65 (1.73-4.06) | <.0001 | 2.03 (0.90-4.60) | 0.089 |